memantale-instruction
memantale-instruction

MEMANTALE ® (Memantine)

Clear
Bulk deal
Quantity Discount Discounted price
2 10% -
3 14% -
4 16% -
5 + 18% -
Bulk pricing will be applied to package:

Buy Memantale (Memantine) with 37 day fast domestic delivery within the US ($5)  just choose “Ships from: US (+15%)”

Synthesized by Eli Lilly and Company in 1968, Memantine is one of the few pharmaceuticals approved by the FDA to be used treatment of moderate-to-severe Alzheimer’s disease. Off-label Memantine can also be used for reversing tolerance for caffeine, nicotine, and opioids; it might also be taken for treatment of generalized anxiety disorder.

In the body, Memantale reduces certain types of brain activity by binding to NMDA receptors and blocking the activity of glutamate. As a result, it upregulates receptors in the brain and has a cognitive-enhancing effect.

The medication is, in general, well-tolerated. Side effects are likely to occur if the dosage accumulated in the body is too high. Memantine side effects include confusion, drowsiness, headache, agitation, and hallucinations.

Note: Supplement half-life is 60–100 hours, therefore caution should be exerted when tapering up after the first days of use.

Produced by Sotex, Russia.

Check out other nootropics!


Legal Disclaimer
This product has not been approved by the US FDA. All statements on this page are for informational purposes only and have not been evaluated by the US FDA.
This product is not intended to diagnose, treat, cure, or prevent any disease. See more

Dosage and administration

Memantine starting dosage is 5 mg daily, which can slowly be tapered up to 10–15 mg, depending on the indication.

Side effects

The medication is, in general, well-tolerated. Side effects are likely to occur if the dosage accumulated in the body is too high. Memantine side effects include confusion, drowsiness, headache, agitation, and hallucinations.

Note

Supplement half-life is 60–100 hours, therefore caution should be exerted when tapering up after the first days of use.

Manufacturer

Sotex Pharm Firm, Russia.

  1. M Rogawski, G Wenk (2003) The neuropharmacological basis for the use of memantine in the treatment of Alzheimer’s disease https://www.ncbi.nlm.nih.gov/pubmed/14530799
  2. Reisberg et al (2003) Memantine in moderate-to-severe Alzheimer’s disease https://www.ncbi.nlm.nih.gov/pubmed/12672860
  3. Mobius et al (2004) Memantine hydrochloride: pharmacological and clinical profile https://www.ncbi.nlm.nih.gov/pubmed/15510240
  4. R Tampi, C van Dyck (2007) Memantine: efficacy and safety in mild-to-severe Alzheimer’s disease https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2654628/
  5. Charles et al (2007) Memantine for prevention of migraine: a retrospective study of 60 cases https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3451671/
  6. H Kavirajan, L Schneider (2007) Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials https://www.ncbi.nlm.nih.gov/pubmed/17689146
  7. Farlow et al (2008) Memantine for the treatment of Alzheimer’s disease: tolerability and safety data from clinical trials https://www.ncbi.nlm.nih.gov/pubmed/18558791
  8. Porsteinsson et al (2008) Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial https://www.ncbi.nlm.nih.gov/pubmed/18288936
  9. Clerici et al (2009) Memantine in moderately-severe-to-severe Alzheimer’s disease: a postmarketing surveillance study https://www.ncbi.nlm.nih.gov/pubmed/19476399
  10. S Thomas, G Grossberg (2009) Memantine: a review of studies into its safety and efficacy in treating Alzheimer’s disease and other dementias https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2762361/
  11. Howard et al (2012) Donepezil and memantine for moderate-to-severe Alzheimer’s disease https://www.ncbi.nlm.nih.gov/pubmed/22397651
  12. Yang et al (2013) Effectiveness and safety of memantine treatment for Alzheimer’s disease https://www.ncbi.nlm.nih.gov/pubmed/23635410
  13. Dysken et al (2014) Effect of Vitamin E and Memantine on Functional Decline in Alzheimer Disease The TEAM-AD VA Cooperative Randomized Trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4109898/
  14. Nakamura et al (2014) Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer’s disease: results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4025599/
  15. Matsunaga et al (2015) Memantine monotherapy for Alzheimer’s disease: a systematic review and meta-analysis https://www.ncbi.nlm.nih.gov/pubmed/25860130
  16. Atri et al (2015) Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer’s dementia: a pooled area under the curve analysis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4436119/
  17. Hager et al (2016) Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer’s disease: post-hoc analysis of a randomized placebo-controlled study https://www.ncbi.nlm.nih.gov/pubmed/27846868
  18. Marimuthu et al (2016) Evaluating the efficacy of memantine on improving cognitive functions in epileptic patients receiving anti-epileptic drugs: A double-blind placebo-controlled clinical trial (Phase IIIb pilot study) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980957/
  19. Kishi et al (2017) Memantine for Alzheimer’s Disease: An Updated Systematic Review and Meta-analysis https://www.ncbi.nlm.nih.gov/pubmed/28922160
  20. Karahmadi et al (2017) Study of the effect of Memantine therapy on the treatment of dyslexia in children https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5767814/
  21. N Titova et al (2017) Memantine: from the original brand to generics https://www.ncbi.nlm.nih.gov/pubmed/29171502
  22. Folch et al (2018) Memantine for the Treatment of Dementia: A Review on its Current and Future Applications https://www.ncbi.nlm.nih.gov/pubmed/29254093
  23. Tavakoli-Ardakani et al (2018) Study of the Effect of Memantine on Negative Sign in Patients with Schizophrenia and Schizoaffective Disorders https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5958331/

Related products

COGITUM ®

$ 120.00$ 138.00

Cogitum is an adaptogen with tonic and stimulating properties. It has a 40-year-long track record of successful application. Cogitum is widely used in pediatrics and child neurology for treating delayed development, asthenic syndrome and for increasing endurance and mental performance in children and adolescents during high loads. It enhances memory due to D-Aspartic acid which is a well-known metabolite.

Biotredin is a nootropic medication which improves metabolism and boosts cellular energy. The drug is comprised of L-threonine and pyridoxine hydrochloride (vitamin B6). Together, threonine and vitamin B6 interact to form:В The amino acid glycine, Acetaldehyde.The resulting substance promotes active stimulation of inhibitory processes, oxidation-reduction, and supports respiratory function, and synthesis of adenosine triphosphate in the cells.

Befungin is a restorative and regenerative medicine based on Chaga mushroom. This preparation stimulates metabolism, restores hematogenesis and strengthens immune system after long-term illnesses.В Befungin contains the extract of a cinder conk (Chaga mushroom which grows on birch trees) with salts of 1.5% cobalt sulphate or 1% cobalt chloride.

ADAPTOL ® (Mebicar)

$ 18.00$ 46.00

Mebicar (or tetramethylglycoluril) is an anxiolytic medication that works on the serotonergic system: taken in small doses it increases the effect of tryptophan, which is a precursor to serotonin. Mebicar purportedly has anti-anxiety properties. It is also used to aid smoking cessation and in the treatment of ADHD symptoms. Mebicar decreases the brain noradrenaline level, exerts no effect on the dopaminergic systems, increases the brain serotonin level, and does not elicit cholinolytic action.